New Advances in the Treatment of Primary Central Nervous System Lymphoma--Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 633-637, 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-880125
ABSTRACT
Primary central nervous system lymphoma (PCNSL) is a rare aggressive non-Hodgkin's lymphoma outside the lymph nodes. At present, high-dose chemotherapy based on methotrexate is the standard induction therapy for newly diagnosed PCNSL, but the effective therapy of relapse/refractory and elderly PCNSL is still unclear. With the progress of clinical trials, new drugs and combined treatment method appear constantly, such as rituximab and ibrutinib, the remission rate of refractory and relapsed patients increased, while lenalidomide showed a good activity in the maintenance treatment of elderly patients. This review summarized briefly the recent advances of research on immunocheckpoint inhibitors, immunoregulatory agents, bruton tyrosine kinase (BTK) and PI3K/AKT/mTOR pathway inhibitors.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Linfoma no Hodgkin
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Sistema Nervioso Central
/
Neoplasias del Sistema Nervioso Central
/
Fosfatidilinositol 3-Quinasas
/
Recurrencia Local de Neoplasia
Límite:
Anciano
/
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS